Skip to main content
OpenTrials
Completed

NCT Number: NCT01155427

Systematic Review of Antiretroviral Treatments for Chronic Hepatitis B (CHB)

The purpose of this study is to support the clinical value of entecavir by assessing the relationship between viral load and histological improvement.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Systematic review of prospective clinical trials

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with CHB diagnosis and no co-infection with Hep A, Hep C, Hep D, or HIV
  • Age 16 years or older
  • No post-transplant patients
  • RCT, non-randomized trials, prospective cohort studies, prospectively analyses case series published since 2003
  • At least one arm of trial must include monotherapy with entecavir, lamivudine, tenofovir, adefovir, or telbivudine
  • Study arms must include at least 10 patients
  • Follow-up of at least 48 weeks
  • Published results available in English language

Exclusion criteria

  • N/A

Treatment and study plan

Primary outcomes

  1. Viral load

  2. Histological improvement

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Registry information

Official study title

A Systematic Review of Literature on Common Antiretroviral Treatments Against Hepatitis B Virus (HBV)

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Jul 1, 2010
Registry last updated
Jul 1, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.